Slide 1: Medistim ASA Second Quarter 2016
Medistim ASA Second Quarter 2016 Kari E. Krogstad, President and CEO Thomas Jakobsen, CFO August 24th, 2016
Slide 2: Disclaimer
2 24.08.2016 Medistim ASA Q2 2016 Disclaimer The information included in this Presentation contains certain forward-looking statements that address activities, events or developments that Medistim ASA (“the Company”) expects, projects, believes or anticipates will or may occur in the future. These s
Slide 3: Table of contents
3 24.08.2016 Medistim ASA Q2 2016 Table of contents 1. Highlights second quarter 2. Financial statements 3. Business segments update 4. Implementing the strategy
Slide 4: 1. Highlights second quarter
1. Highlights second quarter
Slide 5: Highlights second quarter 2016
5 24.08.2016 Medistim ASA Q2 2016 Highlights second quarter 2016 Q2 2016 QoQ • 17.4 % sales growth for the quarter o Sales of own products increased with 22.2 % to Revenue 17.4% MNOK 47.7 MNOK 67.2 (57.3) o All time high US sales up 10.9 % to MNOK 22.7 3. party sales up by 7.0 % to MNOK 19.5 o EBIT
Slide 6: 2. Financial statements
MED\STIM 2. Financial statements
Slide 7: Profit and loss Q2 2016
7 24.08.2016 Medistim ASA Q2 2016 Profit and loss Q2 2016 Profit & loss Q2 2016 Q2 2015 All numb ers in NOK 1000 Sales per Quarter (TNOK) Sales 67 194 57 254 80 000 Cost of goods sold 17 322 13 787 70 000 Salary and sosial expenses 18 692 15 513 60 000 Other operating expenses 11 217 10 365 Total op
Slide 8: Profit and loss H1 2016
8 24.08.2016 Medistim ASA Q2 2016 Profit and loss H1 2016 Profit & loss YTD 2016 YTD 2015 All numb ers in NOK 1000 Sales per Quarter (TNOK) Sales 132 694 115 161 80 000 Cost of goods sold 33 009 30 767 70 000 Salary and sosial expenses 41 088 34 377 60 000 Other operating expenses 22 261 20 005 Tota
Slide 9: Balance sheet - Assets
9 24.08.2016 Medistim ASA Q2 2016 Balance sheet - Assets Balance sheet 30.06.2016 31.12.2015 All numb ers in NOK 1000 Assets 250 000 200 000 Intangible assets 53 868 55 122 Fixed assets 16 469 14 158 150 000 Total intangible and fixed assets 70 337 69 280 100 000 Inventory 60 453 46 613 50 000 Custo
Slide 10: Balance sheet - Equity and liability
10 24.08.2016 Medistim ASA Q2 2016 Balance sheet - Equity and liability Balance sheet 30.06.2016 31.12.2015 All numb ers in NOK 1000 250 000 Share capital 4 585 4 585 Premium fund 41 852 41 852 200 000 Other equity 101 841 109 727 150 000 Total equity 148 278 156 164 100 000 Total long term debt 4 7
Slide 11: 3. Business segments update
MED\STIM 3. Business segments update
Slide 12: Flow probes and systems in units
12 24.08.2016 Medistim ASA Q2 2016 Flow probes and systems in units Flow probes in units (excl USA) Flow systems in units (VeriQ & MiraQ) 1 900 35 1 800 30 1 700 25 1 600 20 1 500 15 1 400 10 1 300 5 1 200 0 1 100 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 1 000 14 14 14 14 15 15 15 15 16 16 Q2 Q3 Q4 Q1 Q2 Q3 Q4
Slide 13: Imaging probes and systems in units
13 24.08.2016 Medistim ASA Q2 2016 Imaging probes and systems in units Imaging probes in units (incl USA) Imaging systems in units (VeriQC & MiraQ) 30 30 25 25 20 20 15 10 15 5 10 0 5 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 14 14 14 15 15 15 15 16 16 0 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Imaging probes US imaging probes
Slide 14: Q2 revenue performance by region
14 24.08.2016 Medistim ASA Q2 2016 Q2 revenue performance by region Mill NOK Q2 '16 Q2 '15 Q/Q H1 2016 H1 2015 Y/Y Europe 38,1 31,6 20,3 % 69,8 65,0 7,3 % USA 22,7 20,5 10,9 % 45,7 36,5 24,9 % Asia & Jp 4,0 2,9 40,4 % 11,2 8,7 28,0 % ROW 2,4 2,3 5,7 % 6,1 4,9 25,1 % (MEA, CAN, SA) Total 67,2 57,3 17
Slide 15: Q2 revenue performance by product
15 24.08.2016 Medistim ASA Q2 2016 Q2 revenue performance by product Mill NOK Q2 '16 Q2 '15 Q/Q H1 2016 H1 2015 Y/Y Procedures (USA) 20,3 17,9 13,5 % 40,8 33,3 22,5 % Flow probes 17,6 15,0 17,6 % 34,8 28,8 20,9 % Flow systems (VeriQ & MiraQ) 4,1 3,4 19,3 % 8,4 6,1 37,2 % Imaging systems (VeriQ C & M
Slide 16: 4. Implementing the strategy
4. Implementing the strategy
Slide 17: Growth opportunities – in developing Medistim markets
17 24.08.2016 Medistim ASA Q2 2016 Growth opportunities – in developing Medistim markets 1. Convert the routine Flow market to a Flow-and- Imaging market by establishing Surgical Guidance and Quality Assessment as the new standard of care through Emerging, high-growth o Early adopter & KOL support e
Slide 18: High performance US sales organization
18 24.08.2016 Medistim ASA Q2 2016 45000 40000 High performance US sales organization 35000 30000 25000 20000 2010 2011 2012 2013 2014 2015 Number of procedures per year RESULTS H1 2016 # of Procedures per Consecutive Quarter • Revenues up by 24.9 % in NOK • 14.3 % growth in USD 12 500 11 500 • Numb
Slide 19: Growth opportunities – in strong Medistim markets
19 24.08.2016 Medistim ASA Q2 2016 Growth opportunities – in strong Medistim markets 1. Convert the routine Flow market to a Flow-and- Imaging market by establishing Surgical Guidance and Quality Assessment as the new standard of care through Emerging, high-growth o Early adopter & KOL support econo
Slide 20: Medistim technologies gain reimbursement in Japan
20 24.08.2016 Medistim ASA Q2 2016 Medistim technologies gain reimbursement in Japan • Valid from 1st April 2016, the Ministry of Health, Labour and Welfare in Japan approved a reimbursement of YEN 25,000 [EUR 225] when graft blood flow is controlled, using either transit time flow measurement or hi
Slide 21: 20 largest share holders (per 22. august 2016)
21 24.08.2016 Medistim ASA Q2 2016 20 largest share holders (per 22. august 2016) SHARE HOLDER Number of shares per 22.08.16 INTERTRADE SHIPPING 3 850 000 SALVESEN & THAMS INV 1 862 500 STENSHAGEN INVEST AS 1 511 729 PROTECTOR FORSIKRING 1 196 498 SKAGEN VEKST 1 070 072 FOLLUM CAPITAL AS 1 000 000 H
Slide 22: Seeing is believing
22 24.08.2016 Medistim ASA Q2 2016 Seeing is believing